CTLA-4 blockade was a feasible approach for the treatment of patients with relapsed hematologic cancer after transplantation. Complete remissions with some durability were observed, especially in extramedullary AML. The gene discussed is CTLA4; the disease is hematopoietic and lymphoid cell neoplasm.